MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Caffeine Intake Interacts with Gene Variants in Parkinson’s disease

    E. Tan, Y. Ong, X. Deng, H. Li, D. Heng, K. Narasimhalu, L. Chan, P. Kumar, W. Au, P. Ratnagopal, L. Tan (Singapore, Singapore)

    Objective: We investigate interactions of caffeine intake with PD risk variants and determine PD risk estimates in caffeine-drinkers carrying these variants. Background: Caffeine intake reduces…
  • 2023 International Congress

    Altered nucleus accumbens functional connectivity precedes apathy in Parkinson’s disease

    L. Morris, S. Harrison, T. Melzer, J. Dalrymple-Alford, T. Anderson, M. Macaskill, C. Le Heron (Christchurch, New Zealand)

    Objective: To investigate whether changes in connectivity between neural regions that are associated with goal-directed behaviour predict future development of apathy in people with Parkinson’s…
  • 2023 International Congress

    Towards smart glasses for improved care of individuals with Parkinson’s disease

    I. Kiprijanovska, F. Panchevski, S. Stankoski, M. Gjoreski, J. Archer, J. Broulidakis, I. Mavridou, B. Hayes, T. Guerreiro, C. Nduka, H. Gjoreski (Brighton, United Kingdom)

    Objective: To evaluate the applicability of sensor-enabled smart glasses for remote tracking of symptoms related to Parkinson’s disease Background: Diagnosis and monitoring of PD by…
  • 2023 International Congress

    Trial protocol: Randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson’s disease (MOST-ABLE study)

    Y. Kimura, T. Koda, H. Kurakami, S. Sakamoto, K. Iwasaki, H. Mochizuki (Suita, Osaka, Japan)

    Objective: This study aims to assess efficacy and disease modifying effect, safety, and optimal dose of oral semaglutide tablet, glucagon-like peptide-1 receptor agonists (GLP-1RAs), for…
  • 2023 International Congress

    Metabolic modulation of mitochondrial DNA release in cellular models of Parkin-associated Parkinson’s disease

    G. Agyeah, P. Antony, K. Wasner, A. Rakovic, S. Pereira, A. Grünewald (Esch-Sur-Alzette, Luxembourg)

    Objective: Our objective in this study was to elucidate the mechanisms underlying the release of mtDNA in cellular models of Parkin-associated Parkinson’s disease and to…
  • 2023 International Congress

    Explainable deep learning based detection of Parkinson’s changes in MRI brain scans

    M. Courtman, M. Thurston, L. Mcgavin, C. Carroll, L. Sun, E. Ifeachor, S. Mullin (Plymouth, United Kingdom)

    Objective: A pilot study using an AI-based framework to classify routine brain scans as Parkinson’s disease (PD) or control. Background: Prospective neuroprotective treatments for PD…
  • 2023 International Congress

    Brain FDG-PET-MRI for early diagnosis of corticobasal syndrome

    I. Guan, C. Stahl, K. Astudillo, T. Shepherd, S. Frucht, G. Riboldi (New York, USA)

    Objective: To characterize brain fluorodeoxyglucose (FDG) PET-MRI findings in patients with corticobasal syndrome (CBS) and evaluate its utility in early diagnosis of Corticobasal Degeneration (CBD)…
  • 2023 International Congress

    Predictive model for Identification of device-aided therapy (DAT) Candidates in Parkinson´s Disease (DELIST-PD Study)

    E. Freire-Alvarez, I. Legarda Ramirez, R. Garcia-Ramos, F. Carrillo, D. Santos-Garcia, JC. Gomez-Esteban, JC. Martinez-Castrillo, I. Martinez-Torres, CJ. Madrid Navarro, MJ. Perez Navarro, F. Valero Garcia, B. Vives Pastor, L. Muñoz-Delgado, B. Tijero, C. Morata-Martinez, R. Aler, IM. Galvan, F. Escamilla-Sevilla (Elche, Spain)

    Objective: To develop a classification algorithm based on machine learning to identify candidates for device-aided therapy among patients with Parkinson's disease (PD). Background: DATs (deep…
  • 2023 International Congress

    Correlation between fatigue, sleep dysfunction and health-related quality of life in Parkinson’s disease patients

    EL. Ungureanu, S. Berzunțeanu, ș. Diaconu, A. Zârnoveanu, T. Drăgan, B. Ciocănescu, R. Filip, N. Enache, C. Falup-Pecurariu (Brasov, Romania)

    Objective: To determine the correlation between fatigue, sleep dysfunction and health-related quality of life in Parkinson’s disease (PD) patients. Background: Fatigue and sleep dysfunction are…
  • 2023 International Congress

    Obesity is a protective factor for the development of Parkinson’s disease in participants of the Framingham Heart Study Cohort

    S. O'Shea, Y. Liu, C. Liu, S. Frank, R. Au (New York, USA)

    Objective: To determine the role of obesity in the development of Parkinson's disease in a retrospective matched cohort study. Background: Parkinson’s disease (PD) is a…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley